<DOC>
	<DOCNO>NCT02742727</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness CAR-pNK cell immunotherapy patient CD7 positive relapse refractory Leukemia Lymphoma .</brief_summary>
	<brief_title>CAR-pNK Cell Immunotherapy CD7 Positive Leukemia Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Leukemia , Large Granular Lymphocytic</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic , T-Cell</mesh_term>
	<mesh_term>Enteropathy-Associated T-Cell Lymphoma</mesh_term>
	<mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<criteria>Male female subject CD7+ malignancy patient available curative treatment option limit prognosis ( several month &lt; 2 year survival ) currently available therapy enrol : 1 . Eligible disease : CD7 positive relapse refractory Leukemia Lymphoma . ￚ Acute myeloid leukemia , previously identify CD7+ ￚ Precursor T lymphoblast leukemia/lymphoma ￚ Tcell prolymphocytic leukemia ￚ Tcell large granular lymphocytic leukemia ￚ Peripheral Tcell lymphoma , NOS ￚ Angioimmunoblastic Tcell lymphoma ￚ Extranodal NK/Tcell lymphoma , nasal type ￚ Enteropathytype intestinal Tcell lymphoma ￚ Hepatosplenic Tcell lymphoma 2 . Patients 18 year age old , must life expectancy &gt; 12 week . 3 . CD7 express malignancy tissue immunohistochemical ( IHC ) Flow cytometry . 4 . Assessable disease measure laboratory bone marrow examination . 5 . Eastern cooperative oncology group ( ECOG ) performance status 02 karnofsky performance status ( KPS ) score high 60 . 6 . Females childbearing potential must negative pregnancy test subject must agree use effective method contraception two week last infusion CARpNK cell . 7 . Adequate bone marrow , liver renal function assess follow laboratory requirement : serum creatinine ≤ 2.5mg/dL , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 5×upper limit normal , serum total bilirubin ≤ 2.0mg/dL . These test must conduct within 7 day prior registration . 8 . Ability give inform consent . 1 . Patients symptomatic central nervous system ( CNS ) involvement . 2 . Pregnant nursing woman may participate . 3 . Known HIV , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection . 4 . Serious illness medical condition would permit patient manage accord protocol , include active uncontrolled infection , major cardiovascular , coagulation disorder , respiratory immune system , myocardial infarction , cardiac arrhythmia , obstructive/restrictive pulmonary disease , psychiatric emotional disorder . 5 . Concurrent use systemic steroid . Recent current use inhale steroid exclusionary . 6 . Previously treatment gene therapy product . 7 . The existence unstable active ulcer gastrointestinal bleeding . 8 . Patients history organ transplantation wait organ transplantation . 9 . Patients need anticoagulant therapy ( warfarin heparin ) . 10 . Patients need longterm antiplatelet therapy ( aspirin dose &gt; 300mg/d ; clopidogrel dose &gt; 75mg/d ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>